

# MIELOMA NEWS

## Bart Barlogie

### Professional Experience

1970-1971 Internship, Internal Medicine, University of Munich, Munich, Germany  
1971-1974 Residency, Internal Medicine, Rheumatology, Nephrology, Cardiology, Hematology, Infectious Diseases, Gastroenterology, University of Muenster Medical School  
1976-1977 Project Investigator, Dept. of Developmental Therapeutics, MD Anderson Hospital & Tumor Institute, Houston, TX  
1977-1979 Assistant Professor, Medicine, Dept. of Developmental Therapeutics, MD Anderson  
1978-1982 Assistant Professor, Dept. of Internal Medicine, University of Texas Medical School, Houston, TX; Acting Chief of Oncology Service  
1979-1983 Associate Professor, Medicine, Dept. of Developmental Therapeutics, MD Anderson  
1979-1983 Associate Professor, Medicine, Dept. of Internal Medicine, University of Texas Medical School  
1978-1989 Professor, Medicine, Graduate School of Biomedical Sciences, University of Texas  
1983-1989 Professor, Medicine, Dept. of Hematology, MD Anderson  
1985-1987 Ad Interim Chairman, Dept. of Hematology, MD Anderson  
1985-1989 Chief, Experimental Hematology, Dept. of Hematology, Div. of Medicine, MD Anderson  
1989-present Adjunct Professor, Medicine, Dept. of Hematology, Div. of Medicine, MD Anderson  
1989-1997 Professor, Medicine and Pathology, Director, Div. of Hematology/Oncology, University of Arkansas for Medical Sciences (UAMS); Director of Research, Arkansas Cancer Research Center (ACRC), UAMS  
1997-1998 Professor, Medicine and Pathology, Director, Myeloma & Transplantation Research Center, UAMS; Director of Research, ACRC  
1998-2001 Professor, Medicine and Pathology, Director, ACRC, UAMS  
2001-present Professor, Medicine and Pathology, Director, Myeloma Institute for Research and Therapy, UAMS

### Research Support, Ongoing

Multiple Myeloma Research Foundation Grant (Qiang, PI) 2/1/11–3/31/13  
Identification of Molecular Targets in Myeloma Microenvironment  
The aim of this project is to identify molecular targets in cadherin-modulated signaling pathways that contribute to myeloma pathogenesis in bone marrow microenvironments.  
Role: Co-Investigator  
SP01CA095819-17 (Barlogie, PI) 9/1/09–8/31/14  
NCI  
Growth Control in Multiple Myeloma  
The overall objective of this P01 is to understand mm growth in the context of its interaction with the bone marrow microenvironment (ME) in order to translate and exploit this knowledge into smarter MM growth control in patients. A concerted effort by a highly integrated and synergistic team of basic and clinical scientists is aimed at further overcoming the tremendous obstacles posed by MM's extensive genetic heterogeneity. We hypothesize that MM subjugates various ME components, perhaps in a MM subtype-specific manner, and that such MM-induced ME imprints may become an irreversible force, contributing

### Simposio Internacional “Mieloma Múltiple, una cura es posible”

Jueves 24 de mayo de 2012 a las 19.30 horas.

Hotel Sheraton–Santiago.



### Honors

The Best Doctors in America, 1994, 1998  
Distinguished Faculty Scholar Award UAMS, 1995  
Distinguished Faculty, Arkansas Caduceus Club, 1997  
Distinguished Alumnus Award, MD Anderson Cancer Center, 1998  
Jan Waldenström Award for Myeloma Research, 1999  
Celgene Career Achievement Award in Hematology Research, 2002  
Francesca M. Thompson Outstanding Service Award (IMF), 2003  
Robert A. Kyle Lifetime Achievement Award (IMF), 2004  
Castle Connolly Medical Ltd., National Physician Award of the Year - 2006  
Tommy May Chair in Oncology, 2006

### Selected Publications

1.Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents.N Engl J Med. 1984 May 24;310(21):1353-6.PMID: 6546971  
2.Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.N Engl J Med. 1994 Mar 3;330(9):602-5. No abstract available. PMID: 8302342  
3.Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003 Dec 25;349(26):2483-94. PMID: 14695408  
4.Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orloffski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17. PMID: 12826635  
5.Barlogie B. The role of transplant in multiple myeloma. Clin Adv Hematol Oncol 2005; 3: 604-606. PMID:16167043  
6.Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Hematol 2005; 131: 71-73. PMID:16399589  
7.Shaughnessy JD Jr, Barlogie B. Using genomics to identify high-risk Myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 2006; 12 (1 Suppl 1):77-80. PMID:16399589  
8.Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. N Engl J Med 2006; 354:1021-1030. PMID:16525139



TECNOFARMA

